VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | Genomically aggressive or indolent smoldering myeloma and progression to multiple myeloma

Niccolò Bolli, MD, PhD, University of Milan, Milan, Italy, comments on features that are characterized as genomically aggressive or indolent in patients with smoldering myeloma, and discusses their impact on progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter